Clinical characteristics of 416 patients with t-MNs
| . | Total . | t-AML . | t-MDS . | P value . |
|---|---|---|---|---|
| N | 416 | 167 | 249 | |
| Median age (range), y | 68 (17-91) | 65 (17-89) | 69 (22-91) | .002 |
| Male, n (%) | 221 (53) | 79 (47) | 143 (57) | .051 |
| Median latency (range), y | 6.0 (0.1-40) | 5.0 (0.1-40) | 6.4 (0.3-45) | .028 |
| Median Hgb (range), g/dL | 9.3 (5.2-14.8) | 9.3 (5.2-13.2) | 9.3 (5.9-14.8) | .079 |
| Median WBC (range), K/μL | 3.2 (0.1-267) | 3.8 (0.1-267) | 3 (0.2-85.7) | .000 |
| Median ANC (range), K/μL | 1.17 (0-62.5) | 0.98 (0-62.5) | 1.3 (0-50.6) | .170 |
| Median PLT (range), K/μL | 58 (3-895) | 41 (3-389) | 65 (6-895) | .002 |
| Previous malignancy, n (%) | .000 | |||
| Nonhematological | 285 (63) | 142 (78) | 143 (52) | |
| Hematologic | 169 (37) | 39 (22) | 130 (48) | |
| Active primary malignancy, n (%) | 63 (15) | 11 (7) | 52 (21) | .000 |
| Previous therapy, n (%) | .053 | |||
| Chemotherapy | 186 (45) | 66 (39) | 120 (48) | |
| Radiotherapy | 69 (16) | 36 (22) | 33 (13) | |
| Chemoradiotherapy | 161 (39) | 65 (39) | 96 (39) | |
| History of auto-HSCT, n (%) | 69 (17) | 32 (19) | 37 (15) | .282 |
| Cytogenetics∗, n (%) | ||||
| Diploid | 84 (21) | 34 (21) | 50 (21) | .941 |
| Complex† | 170 (41) | 67 (41) | 103 (43) | .622 |
| Del 5q/-5‡ | 131 (32) | 42 (25) | 89 (37) | .013 |
| Del 7q/-7 | 138 (34) | 33 (20) | 105 (43) | .000 |
| Inv 16/t(16;16) | 6 (1) | 6 (4) | 0 (0) | .003 |
| 11q23 | 29 (7) | 26 (16) | 3 (1) | .000 |
| t(15;17) | 4 (1) | 4 (2) | 0 (0) | .036 |
| t(8;21) | 3 (1) | 3 (2) | 0 (0) | .036 |
| -Y | 16 (4) | 9 (5) | 7 (3) | .201 |
| Del 20q | 38 (9) | 11 (7) | 27 (11) | .118 |
| Del 12p | 42 (10) | 14 (8) | 28 (12) | .297 |
| Trisomy 8 | 60 (15) | 25 (15) | 35 (14) | .887 |
| Inv3q/t(3;3) | 8 (2) | 2 (1) | 6 (2) | .358 |
| Trisomy 21 | 41 (11) | 18 (11) | 23 (10) | .673 |
| Del 17p/-17 | 54 (13) | 22 (13) | 32 (13) | .988 |
| . | Total . | t-AML . | t-MDS . | P value . |
|---|---|---|---|---|
| N | 416 | 167 | 249 | |
| Median age (range), y | 68 (17-91) | 65 (17-89) | 69 (22-91) | .002 |
| Male, n (%) | 221 (53) | 79 (47) | 143 (57) | .051 |
| Median latency (range), y | 6.0 (0.1-40) | 5.0 (0.1-40) | 6.4 (0.3-45) | .028 |
| Median Hgb (range), g/dL | 9.3 (5.2-14.8) | 9.3 (5.2-13.2) | 9.3 (5.9-14.8) | .079 |
| Median WBC (range), K/μL | 3.2 (0.1-267) | 3.8 (0.1-267) | 3 (0.2-85.7) | .000 |
| Median ANC (range), K/μL | 1.17 (0-62.5) | 0.98 (0-62.5) | 1.3 (0-50.6) | .170 |
| Median PLT (range), K/μL | 58 (3-895) | 41 (3-389) | 65 (6-895) | .002 |
| Previous malignancy, n (%) | .000 | |||
| Nonhematological | 285 (63) | 142 (78) | 143 (52) | |
| Hematologic | 169 (37) | 39 (22) | 130 (48) | |
| Active primary malignancy, n (%) | 63 (15) | 11 (7) | 52 (21) | .000 |
| Previous therapy, n (%) | .053 | |||
| Chemotherapy | 186 (45) | 66 (39) | 120 (48) | |
| Radiotherapy | 69 (16) | 36 (22) | 33 (13) | |
| Chemoradiotherapy | 161 (39) | 65 (39) | 96 (39) | |
| History of auto-HSCT, n (%) | 69 (17) | 32 (19) | 37 (15) | .282 |
| Cytogenetics∗, n (%) | ||||
| Diploid | 84 (21) | 34 (21) | 50 (21) | .941 |
| Complex† | 170 (41) | 67 (41) | 103 (43) | .622 |
| Del 5q/-5‡ | 131 (32) | 42 (25) | 89 (37) | .013 |
| Del 7q/-7 | 138 (34) | 33 (20) | 105 (43) | .000 |
| Inv 16/t(16;16) | 6 (1) | 6 (4) | 0 (0) | .003 |
| 11q23 | 29 (7) | 26 (16) | 3 (1) | .000 |
| t(15;17) | 4 (1) | 4 (2) | 0 (0) | .036 |
| t(8;21) | 3 (1) | 3 (2) | 0 (0) | .036 |
| -Y | 16 (4) | 9 (5) | 7 (3) | .201 |
| Del 20q | 38 (9) | 11 (7) | 27 (11) | .118 |
| Del 12p | 42 (10) | 14 (8) | 28 (12) | .297 |
| Trisomy 8 | 60 (15) | 25 (15) | 35 (14) | .887 |
| Inv3q/t(3;3) | 8 (2) | 2 (1) | 6 (2) | .358 |
| Trisomy 21 | 41 (11) | 18 (11) | 23 (10) | .673 |
| Del 17p/-17 | 54 (13) | 22 (13) | 32 (13) | .988 |
Bold denotes variables with P < .05.
ANC, absolute neutrophil counts; auto-HSCT, autologous hematopoietic stem cell transplant; Hgb, hemoglobin; PLT, platelet; WBC, white blood cell count.
Cytogenetic abnormalities were recorded either as a sole abnormality or with multiple other abnormalities; therefore, the total frequency exceeds 100%.
Among patients with complex karyotype, 40 (25%) did not have chromosome 5 or 7 abnormalities.
Seventy-nine patients (19%) had concurrent chromosome 5 and 7 abnormalities.